Will antimicrobial resistance outpace research?

The article focuses on a main takeaway from the report: the shrinking pipeline of antimicrobial projects by large, research-based pharmaceutical companies, which declined by more than one-third since the last iteration of the report was published in 2021.

It quotes Jayasree Iyer, CEO of the Access to Medicine Foundation, saying the data in the new report “tells a bit of a sobering story,” including a shrinking pipeline for both adult and paediatric products.

It also touches on the role of small- and medium-sized enterprises in the space, which have become instrumental in the research and development of new products, but lack the resources and reach to tackle the challenege of AMR alone.